Watch our video on Glycoconnect

Enabling significant more effective and safer ADCs that are easier to manufacture

Like Comment

Synaffix is a Netherlands-based biotech enabling highly-competitive product candidates using its site-specific antibody-drug conjugate (ADC) technology platform, comprised of GlycoConnect™ and HydraSpace™.  The platform consistently delivers safer and more effective ADCs compared to all 3 major clinical-stage approaches.  

Synaffix' business model is technology out-licensing where granted patents provide end-to-end protection of the technology as well as resulting product candidates thru at least 2035.

We anticipate the first-in-human studies evaluating Synaffix ADC technology to be initiated by our partners in 2018.

Watch our video on Glycoconnect:

Go to the profile of Synaffix


Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture.

No comments yet.